Business Wire

Vivior and SwissLens establish collaboration for the development of personalized contact lenses

2.12.2019 14:56:00 EET | Business Wire | Press release

Share

Both Swiss companies agreed to collaborate in the field of personalized multifocal soft contact lenses for presbyopia correction. The objective is to optimize the design in soft multifocal contact lenses by using the data generated by Vivior’s visual behavior monitor, the Vivior Monitor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191202005453/en/

“The cooperation with SwissLens represents another milestone for Vivior. With SwissLens we have an established Swiss company as a partner in the growing field of multifocal personalized contact lenses. Both cooperation partners pursue the goal of achieving better vision comfort for customers and patients and complement each other perfectly in terms of technology,” says Andreas Kelch, Sales & Marketing Manager Vision Care at Vivior.

“With Vivior's innovative monitoring system, we obtain objective measurement data of visual behavior that are still unknown today. As a manufacturer of individual lenses, we can incorporate this data into the development of innovative new multifocal lenses. We are pleased about the partnership and the possibly resulting optimized lens designs that should enable the wearer to see better in all areas of vision,” explains Pascal Blaser, Head of Sales and R&D leader at SwissLens.

About SwissLens
Since 1997, SwissLens in Prilly, near Lausanne (Switzerland), has been manufacturing individual contact lenses of the highest quality and distributing them to eye specialists in over 25 countries. Thanks to extensive research, patented and innovative manufacturing technologies, SwissLens is constantly developing its products and services.

www.swisslens.ch

About Vivior
Vivior is a Swiss digital health start-up founded in 2017 by a group of experienced eye care professionals. The company offers a novel wearable device – the Vivior Monitor – to objectively measure visual behavior prior to vision correction interventions. The system collects daily activity data from customers and patients, processes these data in the cloud, and analyzes the lifestyle patterns using machine-learning algorithms. This ground-breaking combination allows to understand better the needs of customers and patients and enables eye care professionals to offer optimal personalized solutions to them. In addition, Vivior develops personalized spectacle, contact and intraocular lenses for vision correction in collaboration with various partners. The goal is to achieve better vision comfort for customers and patients based on the data generated by the Vivior Monitor.
www.vivior.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information, please contact:
Vivior AG
Mario Stark, CEO
mario.stark@vivior.com
+41 79 542 88 74

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye